TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $144.25.

Several research firms have commented on TMDX. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Morgan Stanley boosted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Needham & Company LLC raised their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th.

Insider Activity

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 8,920 shares of company stock worth $1,257,310 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its stake in shares of TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after buying an additional 394,340 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares during the last quarter. Two Sigma Investments LP grew its position in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares during the period. Wellington Management Group LLP increased its stake in shares of TransMedics Group by 100.5% during the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock worth $52,713,000 after purchasing an additional 217,180 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after purchasing an additional 171,810 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $134.25 on Friday. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The firm has a market cap of $4.59 billion, a price-to-earnings ratio of 54.35 and a beta of 2.06. The stock’s 50-day moving average is $132.50 and its 200-day moving average is $125.87. TransMedics Group has a one year low of $62.07 and a one year high of $156.00.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.